Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHUK | O15111 | 18/20 | 0.65 |
| ▸ | ICOSLG | O75144 | 8/20 | 0.50 |
| ▸ | ICOS | Q9Y6W8 | 8/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | IKBKB | O14920 | 1/20 | 0.47 |
| ▸ | PIM1 | P11309 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.47 |
| ▸ | IKBKG | Q9Y6K9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30664284 | 1.00 | CHUK (0.65) | CHUKICOSLGICOSMEN1IKBKB | |
| SCHEMBL20122971 | 0.83 | CHUK (0.60) | CHUKICOSLGICOSMEN1IKBKB | |
| SCHEMBL30664319 | 0.83 | CHUK (0.60) | CHUKICOSLGICOSMEN1IKBKB | |
| SCHEMBL30664138 | 0.81 | CHUK (0.61) | CHUKICOSLGICOS | |
| SCHEMBL30664350 | 0.81 | CHUK (0.58) | CHUKICOSLGICOSMEN1IKBKB | |
| SCHEMBL20122946 | 0.81 | CHUK (0.61) | CHUKICOSLGICOS | |
| SCHEMBL20122974 | 0.81 | CHUK (0.58) | CHUKICOSLGICOSMEN1IKBKB | |
| SCHEMBL5264210 | 0.79 | CHUK (1.00) | CHUKICOSLGICOSMEN1IKBKB | |
| SCHEMBL20122970 | 0.78 | CHUK (0.55) | CHUKICOSLGICOSMEN1IKBKB | |
| SCHEMBL30664253 | 0.78 | CHUK (0.55) | CHUKICOSLGICOSMEN1IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827633-B2 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders | SANOFI (FR) | 2023-11-28 | — | — | US | disclosed |
| US-11827633-B2 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders | SANOFI (FR) | 2023-11-28 | — | — | US | disclosed |
| US-11130755-B2 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders | SANOFI (FR) | 2021-09-28 | — | — | US | disclosed |
| EP-3792262-A1 | SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS | SANOFI (FR) | 2021-03-17 | — | — | EP | disclosed |
| EP-3792262-A1 | SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS | SANOFI (FR) | 2021-03-17 | — | — | EP | disclosed |
| EP-3535263-B1 | SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS | SANOFI SA (FR) | 2020-09-30 | — | — | EP | disclosed |
| EP-3318563-A1 | SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS | SANOFI (FR) | 2018-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827633-B2 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders | COL2A1, IDO1, COL1A1 | CHUK 1582/4885ICOSLG 906/4885ICOS 1550/4885 |
| US-11130755-B2 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders | COL2A1, IDO1, COL1A1 | CHUK 1582/4885ICOSLG 906/4885ICOS 1550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.